Minoxidil Hair Loss Drug: New Concerns for Infants & Eye Health Revealed

• Global safety analysis links Minoxidil to over 45 cases of excessive hair growth in infants (up to 23 months), often from indirect exposure.
• Over 1,660 eye-related side effects reported globally, including eyelid swelling, blurred vision, and serious conditions like Central Serous Chorioretinopathy.
• The study, based on WHO's VigiBase data, highlights risks from Minoxidil's easy availability, aggressive promotion, and lack of awareness.
• Minoxidil is dangerous during pregnancy and breastfeeding, with transfer to infants possible through skin contact or household surfaces.
• Researchers recommend clear warning labels, strict OTC control, and counseling to prevent unintentional harm.

Why It Matters: Minoxidil, a popular hair loss drug, poses significant risks to infants and eye health, necessitating urgent safety measures.